Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Merck KGaA divests allergy business to Dermapharm

The sum of the agreement remains undisclosed

- PMLiVE

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo

- PMLiVE

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year

- PMLiVE

Lucid Group shine the spotlight on mental and physical health

Lucid kick-started its health and wellbeing agenda for the year with a focus on physical and mental wellbeing by taking inspiration from an elite sportsman, James Rodwell. James, a decorated...

Lucid Group Communications Limited

- PMLiVE

Novo Nordisk awakens its ‘Sleeping Beauty’

Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott

- PMLiVE

Porterhouse announces members of medical advisory group

Group provides first-hand clinical experience to colleagues and clients

How will the Tories’ historic win shape the NHS?

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond

Wilmington Healthcare

Porterhouse Medical Advisory Group

Introducing the members of the Porterhouse Medical Advisory Group

Porterhouse is pleased to announce that our Medical Advisory Group has grown, adding further clinical experience and insights from medical doctors to the creation of powerful medical communications.

Porterhouse Medical Group

CSR ‘Christmas Spirit’ 2019

OPEN Health champions CSR over Christmas by giving back to the community and increasing our  activities and efforts

OPEN Health

Spotlight interview: 15 minutes on Independent Medical Education

Celeste Kolanko, Managing Director of Liberum, OPEN Health takes 15 minutes to answer some key questions on independent medical education.

OPEN Health

- PMLiVE

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Revenues down from last year but beat analyst expectations

- PMLiVE

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links